Eur J Pharmacol:Bcl-2抑制剂ABT-737在过敏性鼻炎模型中的抗过敏性和抗炎症作用研究

2018-06-15 AlexYang MedSci原创

抗癌症药物ABT-737被设计用来特异性的抑制抗凋亡蛋白Bcl-2家族。长久以来,人们认为癌症的发展与炎症相关。最近,有研究人员利用体内和体外模型,评估了ABT-737对过敏性鼻炎(AR)的抗过敏和抗炎症作用和潜在的分子机制。研究发现,在体外模型中,ABT-737治疗能够降低一些炎症细胞因子的水平。在激活的人类肥大细胞系,即HMC-1细胞中,通过抑制 caspase-1和 NF-κB激活来降低血管

抗癌症药物ABT-737被设计用来特异性的抑制抗凋亡蛋白Bcl-2家族。长久以来,人们认为癌症的发展与炎症相关。最近,有研究人员利用体内和体外模型,评估了ABT-737对过敏性鼻炎(AR)的抗过敏和抗炎症作用和潜在的分子机制。

研究发现,在体外模型中,ABT-737治疗能够降低一些炎症细胞因子的水平。在激活的人类肥大细胞系,即HMC-1细胞中,通过抑制 caspase-1和 NF-κB激活来降低血管内皮生长因子(VEGF)、胸腺基质淋巴细胞生成素(TSLP)、白介素(IL)-1β、IL-6和肿瘤坏死因子-α(TNF-α)的水平。这些观察在卵清蛋白敏感的AR小鼠中得到了确定。在一个AR动物模型中,ABT-737能够显著的减弱AR的临床症状和AR生物标记的水平,特别是lgE、组胺、缺氧诱导因子-1α、VEGF、TSLP、IL-1β、IL-4、L-5、IL-6、IL-13、TNF-α、细胞间黏附分子-1和巨噬细胞炎症蛋白-2。另外,与AR小鼠相比,ABT-737能够减少caspase-1的活性程度;同时,ABT-737能够减弱肥大细胞和嗜酸细胞到鼻粘膜组织的募集作用水平。

最后,研究人员指出,他们鉴定了ABT-737新的抗炎症和抗过敏性作用。他们的结果表明了ABT-737能够改善过敏性炎症反应,比如AR。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (17)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2046979, encodeId=e67020469e9b4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 29 12:03:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049576, encodeId=d07e20495e67e, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Tue Jun 26 06:03:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787484, encodeId=692a1e87484a0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Aug 05 07:03:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634981, encodeId=3e30163498100, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Dec 05 02:03:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851735, encodeId=49f51851e350b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Nov 06 16:03:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707316, encodeId=4fcc1e0731686, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Apr 30 10:03:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996173, encodeId=e3d019961e395, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 04 23:03:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346748, encodeId=27b9346e4851, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Sep 26 14:03:40 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995528, encodeId=777e1995528cd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Fri Dec 21 05:03:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908432, encodeId=c7361908432c5, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 03 15:03:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2046979, encodeId=e67020469e9b4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 29 12:03:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049576, encodeId=d07e20495e67e, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Tue Jun 26 06:03:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787484, encodeId=692a1e87484a0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Aug 05 07:03:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634981, encodeId=3e30163498100, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Dec 05 02:03:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851735, encodeId=49f51851e350b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Nov 06 16:03:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707316, encodeId=4fcc1e0731686, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Apr 30 10:03:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996173, encodeId=e3d019961e395, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 04 23:03:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346748, encodeId=27b9346e4851, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Sep 26 14:03:40 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995528, encodeId=777e1995528cd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Fri Dec 21 05:03:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908432, encodeId=c7361908432c5, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 03 15:03:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2046979, encodeId=e67020469e9b4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 29 12:03:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049576, encodeId=d07e20495e67e, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Tue Jun 26 06:03:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787484, encodeId=692a1e87484a0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Aug 05 07:03:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634981, encodeId=3e30163498100, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Dec 05 02:03:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851735, encodeId=49f51851e350b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Nov 06 16:03:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707316, encodeId=4fcc1e0731686, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Apr 30 10:03:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996173, encodeId=e3d019961e395, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 04 23:03:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346748, encodeId=27b9346e4851, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Sep 26 14:03:40 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995528, encodeId=777e1995528cd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Fri Dec 21 05:03:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908432, encodeId=c7361908432c5, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 03 15:03:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
    2018-08-05 jj000001
  4. [GetPortalCommentsPageByObjectIdResponse(id=2046979, encodeId=e67020469e9b4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 29 12:03:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049576, encodeId=d07e20495e67e, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Tue Jun 26 06:03:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787484, encodeId=692a1e87484a0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Aug 05 07:03:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634981, encodeId=3e30163498100, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Dec 05 02:03:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851735, encodeId=49f51851e350b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Nov 06 16:03:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707316, encodeId=4fcc1e0731686, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Apr 30 10:03:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996173, encodeId=e3d019961e395, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 04 23:03:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346748, encodeId=27b9346e4851, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Sep 26 14:03:40 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995528, encodeId=777e1995528cd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Fri Dec 21 05:03:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908432, encodeId=c7361908432c5, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 03 15:03:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2046979, encodeId=e67020469e9b4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 29 12:03:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049576, encodeId=d07e20495e67e, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Tue Jun 26 06:03:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787484, encodeId=692a1e87484a0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Aug 05 07:03:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634981, encodeId=3e30163498100, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Dec 05 02:03:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851735, encodeId=49f51851e350b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Nov 06 16:03:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707316, encodeId=4fcc1e0731686, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Apr 30 10:03:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996173, encodeId=e3d019961e395, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 04 23:03:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346748, encodeId=27b9346e4851, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Sep 26 14:03:40 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995528, encodeId=777e1995528cd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Fri Dec 21 05:03:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908432, encodeId=c7361908432c5, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 03 15:03:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
    2018-11-06 jklm09
  6. [GetPortalCommentsPageByObjectIdResponse(id=2046979, encodeId=e67020469e9b4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 29 12:03:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049576, encodeId=d07e20495e67e, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Tue Jun 26 06:03:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787484, encodeId=692a1e87484a0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Aug 05 07:03:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634981, encodeId=3e30163498100, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Dec 05 02:03:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851735, encodeId=49f51851e350b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Nov 06 16:03:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707316, encodeId=4fcc1e0731686, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Apr 30 10:03:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996173, encodeId=e3d019961e395, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 04 23:03:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346748, encodeId=27b9346e4851, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Sep 26 14:03:40 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995528, encodeId=777e1995528cd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Fri Dec 21 05:03:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908432, encodeId=c7361908432c5, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 03 15:03:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2046979, encodeId=e67020469e9b4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 29 12:03:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049576, encodeId=d07e20495e67e, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Tue Jun 26 06:03:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787484, encodeId=692a1e87484a0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Aug 05 07:03:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634981, encodeId=3e30163498100, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Dec 05 02:03:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851735, encodeId=49f51851e350b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Nov 06 16:03:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707316, encodeId=4fcc1e0731686, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Apr 30 10:03:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996173, encodeId=e3d019961e395, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 04 23:03:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346748, encodeId=27b9346e4851, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Sep 26 14:03:40 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995528, encodeId=777e1995528cd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Fri Dec 21 05:03:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908432, encodeId=c7361908432c5, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 03 15:03:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
    2018-11-04 yb6560
  8. [GetPortalCommentsPageByObjectIdResponse(id=2046979, encodeId=e67020469e9b4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 29 12:03:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049576, encodeId=d07e20495e67e, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Tue Jun 26 06:03:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787484, encodeId=692a1e87484a0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Aug 05 07:03:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634981, encodeId=3e30163498100, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Dec 05 02:03:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851735, encodeId=49f51851e350b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Nov 06 16:03:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707316, encodeId=4fcc1e0731686, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Apr 30 10:03:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996173, encodeId=e3d019961e395, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 04 23:03:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346748, encodeId=27b9346e4851, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Sep 26 14:03:40 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995528, encodeId=777e1995528cd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Fri Dec 21 05:03:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908432, encodeId=c7361908432c5, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 03 15:03:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
    2018-09-26 1e145228m78(暂无匿称)

    学习了,谢谢作者分享!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2046979, encodeId=e67020469e9b4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 29 12:03:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049576, encodeId=d07e20495e67e, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Tue Jun 26 06:03:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787484, encodeId=692a1e87484a0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Aug 05 07:03:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634981, encodeId=3e30163498100, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Dec 05 02:03:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851735, encodeId=49f51851e350b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Nov 06 16:03:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707316, encodeId=4fcc1e0731686, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Apr 30 10:03:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996173, encodeId=e3d019961e395, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 04 23:03:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346748, encodeId=27b9346e4851, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Sep 26 14:03:40 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995528, encodeId=777e1995528cd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Fri Dec 21 05:03:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908432, encodeId=c7361908432c5, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 03 15:03:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=2046979, encodeId=e67020469e9b4, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sat Sep 29 12:03:00 CST 2018, time=2018-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2049576, encodeId=d07e20495e67e, content=<a href='/topic/show?id=264555e961a' target=_blank style='color:#2F92EE;'>#抗过敏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55796, encryptionId=264555e961a, topicName=抗过敏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a7b6284, createdName=FukaiBao, createdTime=Tue Jun 26 06:03:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787484, encodeId=692a1e87484a0, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Aug 05 07:03:00 CST 2018, time=2018-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634981, encodeId=3e30163498100, content=<a href='/topic/show?id=cf4f325949' target=_blank style='color:#2F92EE;'>#BCL-2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3259, encryptionId=cf4f325949, topicName=BCL-2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f20922366212, createdName=ms3153534357578991, createdTime=Wed Dec 05 02:03:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851735, encodeId=49f51851e350b, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Tue Nov 06 16:03:00 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707316, encodeId=4fcc1e0731686, content=<a href='/topic/show?id=9948325e6d' target=_blank style='color:#2F92EE;'>#BCL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3257, encryptionId=9948325e6d, topicName=BCL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e84031401266, createdName=ms3323097325231039, createdTime=Tue Apr 30 10:03:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996173, encodeId=e3d019961e395, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Nov 04 23:03:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=346748, encodeId=27b9346e4851, content=学习了,谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Wed Sep 26 14:03:40 CST 2018, time=2018-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1995528, encodeId=777e1995528cd, content=<a href='/topic/show?id=992411149e' target=_blank style='color:#2F92EE;'>#2抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1114, encryptionId=992411149e, topicName=2抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28b7142, createdName=liuquan, createdTime=Fri Dec 21 05:03:00 CST 2018, time=2018-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908432, encodeId=c7361908432c5, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sun Feb 03 15:03:00 CST 2019, time=2019-02-03, status=1, ipAttribution=)]

相关资讯

NEJM:经济奖励、电子烟以及戒烟药物效果比较研究

研究发现,经济奖励联合戒烟辅助治疗可获得最高的戒烟效果,单纯的电子烟或戒烟辅助治疗的戒断效果不显著

Eur J Med Res:河北医大二院随机双盲研究称,肾功能差者预防对比剂肾病可用这两种药物

在冠脉介入治疗过程中,经常需要使用对比剂,复杂冠脉病变和慢性闭塞性病变患者更是需要大量的对比剂。但对比剂会造成急性肾损伤,这对于本来就有肾功能不全的患者来说可谓雪上加霜。

关注世卫大会|中国门诊抗菌药物使用率降至8.1%

“今天不采取行动,明天就无药可用。”2010年,世界卫生组织就对全世界敲响了警钟,呼吁加强抗菌药物临床应用管理,遏制细菌耐药。在这场没有硝烟的战争中,我国将行政干预与专业技术紧密结合,持续完善抗菌药物管理体系,多部门协同制度落地。抗菌药物使用率、使用强度、细菌耐药率等指标进一步改善,管理经验得到了国际同行的认可。措施紧锣密鼓 管理不断加码“我国历来高度重视抗菌药物临床应用管理工作,特别是近10年

“有权尝试法案”让绝症患者使用未获批药物

美国总统特朗普30日签署了被称为“尝试权”的新法案,允许绝症患者使用未获美国食品药品管理局(FDA)批准、处于试验阶段的药物。

盘点:眼科药物及临床治疗研究进展

1. 眼科临床药物研究 Am J Epidemiol:用阿奇霉素治疗沙眼与衣原体ompA多样性之间的关系 加利福尼亚大学旧金山分校的Chin SA近日在Am J Epidemiol发表了一篇文章,他们对大规模使用阿奇霉素导致衣原体遗传多样性降低,并有可能再次导致感染复发的假设进行研究,最终认为其证据不支持ompA多样性与眼睛衣原体传播有关。 先前的研究已经预测到,针对沙眼治疗大规模的

病例分享:口服降糖药物的“默契拍档”

患者,男性,65岁。2年前体检发现空腹血糖9 mmol/L,未诊治。3月前查餐后血糖21 mmol/L,患者自觉多饮、多尿,自行服用二甲双胍500 mg bid,监测空腹血糖为13 mmol/L,餐后血糖17 mmol/L左右。曾自行加用阿卡波糖50 mg tid,因腹胀明显停用。现为优化降糖方案,评估并发症入院治疗。